VRTX - Vertex Pharmaceuticals Incorporated
| Previous Close | 178.90 |
| Open | 179.35 |
| Bid | 171.34 x 800 |
| Ask | 175.69 x 800 |
| Day's Range | 175.05 - 181.09 |
| 52 Week Range | 136.50 - 194.92 |
| Volume | 1,501,672 |
| Avg. Volume | 1,170,700 |
| Market Cap | 44.899B |
| Beta (3Y Monthly) | 1.84 |
| PE Ratio (TTM) | 108.92 |
| EPS (TTM) | 1.61 |
| Earnings Date | Oct 24, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 198.27 |
Markit•7 hours agoSee what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX
- Motley Fool•21 hours ago
Why Proteostasis Therapeutics Tumbled 23.2% on Friday
Some investors booked profits following the company's recent cystic fibrosis trial data.
- American City Business Journals•yesterday
UAB researchers leading way on drug regimen battling cystic fibrosis
A triple combination drug has been shown to be effective in improving lung function for the majority of patients with cystic fibrosis. The new therapy can provide therapeutic benefits for 90 percent of all patients with the disease, according to findings published in the New England Journal of Medicine. Researchers from UAB report the medication, which combines an experimental compound known as VX-659 with two existing medications, tezacaftor and ivacaftor, improved lung function by more than 12 percent. VX-659, along with tezacaftor and ivacaftor, were developed by Boston-based Vertex Pharmaceuticals. In November 2017, the same the combination of tezacaftor and ivacaftor produced a substantial improvement in lung function in patients with cystic fibrosis, with a particular set of mutations in the gene responsible for the disease.
- Simply Wall St.•yesterday
Why Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is A Financially Healthy Company
Investors looking for stocks with high market liquidity and little debt on the balance sheet should consider Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). With a market valuation of US$47.4b, VRTX is a Read More...
- Business Wire•yesterday
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to
- Investor's Business Daily•2 days ago
Growth Stocks Smacked Again As Market Correction Intensifies
Growth stocks faced more selling pressure Thursday as the market correction intensified. Activision plunged on Call of Duty sales concerns.
- Business Wire•2 days ago
Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (VRTX) today announced that eight scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 32nd North American Cystic Fibrosis Conference taking place October 18-20, 2018 in Denver.
- Zacks•3 days ago
Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up?
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•3 days ago
CELG vs. VRTX: Which Stock Should Value Investors Buy Now?
CELG vs. VRTX: Which Stock Is the Better Value Option?
- Business Wire•4 days ago
Vertex to Announce Third Quarter 2018 Financial Results on October 24
Vertex Pharmaceuticals Incorporated (VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
- InvestorPlace•8 days ago
3 High-Reward Stocks From 3 Emerging Trends
Today I want to tell you about three stocks, each in its own emerging trend, that have huge upside potential in the transformative years ahead. Gene editing is just what it sounds like. CRISPR Therapeutics (NASDAQ:CRSP) is one of the three leaders in the gene editing sector.
- American City Business Journals•8 days ago
FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial
CRISPR and Vertex were preparing to test the the ability of a new gene-editing technology, CRISPR/Cas9, in cutting out and replacing disease-causing snippets of DNA when the FDA placed the hold in May.
Market Realist•8 days agoHow Is Vertex Pharmaceuticals Positioned in October?
Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies that treat cystic fibrosis. Vertex Pharmaceuticals has key collaboration agreements with CRISPR Therapeutics (CRSP) to develop treatments for underlying genetic causes of human diseases by using CRISPR-Cas9 technology. It also uses Moderna Therapeutics to develop mRNA (messenger ribonucleic acid) therapeutics for cystic fibrosis, BioAxone to evaluate VX-210 as a treatment for spinal cord injuries, and Parion Sciences to develop epithelial sodium channel inhibitors to treat pulmonary diseases.
Market Realist•8 days agoA Look at Vertex Pharmaceuticals’ Operational Performance
How Is Vertex Pharmaceuticals Positioned in October? Vertex Pharmaceuticals’ (VRTX) cost of sales was $104.38 million in the second quarter of 2018 compared to $71.2 million in the second quarter of 2017. It incurred selling, general, and administrative expenses of $137.3 million in the second quarter of 2018 compared to $127.25 million in the second quarter of 2017.
Market Realist•8 days agoWhat Vertex Pharmaceuticals’ Valuation Trend Indicates
In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.
- Motley Fool•9 days ago
Why CRISPR Therapeutics Stock Is Heading Higher Today
CRISPR Therapeutics' stock is jumping in response to a positive regulatory development for its lead therapy.
- Investopedia•9 days ago
CRISPR Therapeutics Set to Surge After FDA Lifts Hold on Human Trial
The Food and Drug Administration (FDA) has cleared the way for CRISPR Therapeutics Ltd. ( CRSP) and Vertex Pharmaceuticals Inc. ( VRTX) to start testing their genetically engineered treatment for sickle cell disease on U.S. patients. In a press release, the two companies said the FDA has now lifted its clinical hold, enabling them to begin trailing the experimental therapy. At the time, CRISPR and Vertex claimed that CTX001 was placed on hold because the FDA had additional questions as part of its review of the paperwork that companies submit for permission to start a clinical trial.
- CNBC•10 days ago
After-hours buzz: SQ, FLR & more
Check out the companies making headlines after the bell: Square SQ stock tumbled 8 percent in after-hours trading following news that CFO Sarah Friar is stepping down . Friar will stay at the company until December before departing to become CEO of Nextdoor, a localized social network for neighborhoods.
- American City Business Journals•10 days ago
FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial
The FDA has lifted its hold on a highly anticipated gene-editing trial by CRISPR Therapeutics and Vertex Pharmaceuticals, allowing for the first company-backed trial in the U.S. to start by the end of the year.
- MarketWatch•10 days ago
Crispr stock up 8% as company says FDA accepted new-drug application
Shares of Crispr Therapeutics AG rose more than 8% in the extended session Wednesday after the company and Vortex Pharmaceuticals Inc. said the Food and Drug Administration has lifted a clinical hold and has accepted a new-drug application for their gene-editing treatment for sickle-cell disease. Shares of Vortex rose 0.6% after ending the regular trading day down 5%. Crispr shares closed 0.6% lower.
- GlobeNewswire•10 days ago
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
In addition to the acceptance of the IND announced today, CRISPR and Vertex previously announced that they had obtained approvals of Clinical Trial Applications for CTX001 in multiple countries outside the U.S. for both β-thalassemia and SCD. The companies remain on track to initiate a Phase 1/2 clinical study in SCD by the end of 2018 and are currently enrolling patients with transfusion dependent β-thalassemia in a Phase 1/2 trial in β-thalassemia in Europe. The elevation of HbF by CTX001 has the potential to alleviate transfusion-requirements for β-thalassemia patients and painful and debilitating sickle crises for sickle cell patients.
- Zacks•10 days ago
Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Motley Fool•11 days ago
3 Biotech Stocks With Major Incoming Catalysts
These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.
Market Realist•11 days agoAnalysts Are Mostly Positive on Neurocrine Biosciences
Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.
- InvestorPlace•15 days ago
7 Fast-Growing Stocks to Buy Today
For the past nearly 10 years, the Federal Reserve and all the central banks in all the industrialized nations have been managing interest rates to keep them outrageously low until the financial system had a chance to right itself. Royal Dutch Shell (NYSE:RDS.A, NYSE:RDS.B) is one of the biggest players in the global energy markets.
